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Abstract
Both type 2 diabetes (T2D) and chronic hepatitis C (CHC) infection are associated with increased risk of developing
hepatocellular carcinoma (HCC). Cytokines are known to play an important role not only in the mechanisms of insulin
resistance and glucose disposal defects but also in the pathological processes occurring in the liver during viral infection.
We evaluated the serum levels of many cytokines, chemokines, adipokines and growth factors in patients with type 2
diabetes, CHC, CHC-related cirrhosis, CHC and type 2 diabetes and CHC-related cirrhosis and type 2 diabetes by BioPlex
assay. The obtained data evidenced that the serum levels of some proteins are significantly up-regulated in all the patients
or in those with only one disease and are often higher, even if in different amounts, when both diseases are associated. In
particular, our results can be useful for the clinical monitoring of patients because they give specific information in regard to
the progression from CHC to LC and CHD to LCD. Moreover, some molecules have shown significant correlations with
clinical/biochemical data, suggesting the possibility to define mini-panels that can be used as specific markers for the
different disease staging. However, our observations demonstrate that an integrated approach is much more powerful than
isolated measurements to evaluate specific stages of these two complex pathologies (type 2 diabetes and chronic CHC
hepatitis) alone or when they are concomitant in a patient. In fact it has emerged as an accurate, simple, specific,
noninvasive, reproducible and less expensive method that, in future, could be included in routine clinical practice to
monitor the association of type 2 diabetes and/or CHC to liver cirrhosis and, possibly, to cancer, and to improve the
prognosis of these diseases.
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Introduction
Recent epidemiological studies suggest that profound alterations
in glucose homeostasis, as occurs in type 2 diabetes mellitus or
metabolic syndrome, increase the risk of fatty liver disease as well
as of hepatocellular carcinoma (HCC) [1]. In fact, many clinical
and experimental data have demonstrated that type 2 diabetes is
more common among patients with chronic hepatitis C virus than
in those with hepatitis B virus or in the general population [2–4]
and that CHC infection is associated with increased risk of
developing insulin resistance and its major late feature, type 2
diabetes [5–6].
In general, CHC infection itself also increases the risk of HCC,
leading to complications such as chronic hepatitis, hepatocellular
necrosis and inflammation, fibrosis, cirrhosis and HCC. For
patients with CHC-related cirrhosis the risk for development of
HCC is 0.54 to 2.0% per year [7].
Recently type 2 diabetes has been recognized as a cofactor that
can modify the course of CHC infection and can be used as an
independent predictor of HCC. Recent studies have shown that
type 2 diabetes was associated with hepatocarcinogenesis in
patients with CHC infection without liver cirrhosis [8–9].
Therefore, there has been a great interest in the search of possible
specific immunological markers able to follow the progression of
CHC to cirrhosis and HCC also in association with type 2
diabetes.
It is well known that cytokines and chemokines are signaling
molecules involved in the inflammatory as well as in cancer-related
processes [10]. Hence, understanding in patients affected from
cancers the dynamics of the complex interaction network of
cytokines [11], defined ‘‘cytokinome’’ [12], should be very useful
to follow the disease progression and evolution from its early stages
as well as to define therapeutic strategies by using systems biology
approaches [11]. However, many data on cytokines have been
reportedintheliteratureandsometimestheircorrelationappearsto
be difficult. In fact, in the most part of these papers, the researchers
have evaluated only few cytokines by single measurements and,
therefore, both the global inflammation mechanism and the
cytokine relationships are understandable with difficulty [12–13].
In our approach, the serum levels of a panel of numerous
cytokines, chemokines, adipokines and growth factors were
evaluated at the same time by BioPlex assay in patients with
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diabetes (T2D), CHC hepatitis and type 2 diabetes (CHD), CHC-
related cirrhosis and type 2 diabetes (LCD) and in healthy
controls, to identify those molecules that might be useful for
discriminating the various stages of these diseases. In other hands,
the simultaneous quantitative determination of a large panel of
cytokines, able to report the correct ratios and dynamics between
highly and poorly represented molecules, has emerged as an
accurate, simple, specific, noninvasive, reproducible and less
expensive method that, in future, could be included in routine
clinical practice to monitor the association of type 2 diabetes and/
or CHC to liver cirrhosis and, possibly, to cancer, and to improve
the prognosis of these diseases.
Materials and Methods
Patients
In this study we enrolled seventeen patients (6 women, 11 men)
with type 2 diabetes (T2D), twenty patients (11 women, 9 men)
with CHC, twenty patients (12 women, 8 men) with LC, ten
patients (4 women, 6 men) with CHD, ten patients (4 women, 6
men) with LCD, and 20 healthy control subjects (11 women, 9
men). In Table 1 we report the clinical characteristics of all
patients. This choice depended from our interest to study the
association of chronic liver damage leading to cirrhosis in presence
or absence of type 2 diabetes. The ADA criteria were used to
classify patients with the type 2 diabetes [14]: i) fasting plasma
glucose 126 mg/dl (7.0 mmol/l) where fasting is defined as no
caloric intake for at least 8 h or ii) symptoms of hyperglycemia and
a casual plasma glucose 200 mg/dl (11.1 mmol/l) where casual is
defined as any time of day without regard to time since last meal
whereas the classic symptoms of hyperglycemia include polyuria,
polydipsia, and unexplained weight loss, or iii) 2-h plasma glucose
200 mg/dl (11.1 mmol/l) during an OGTT where the test has
been performed as described by the World Health Organization,
using a glucose load containing the equivalent of 75 g anhydrous
glucose dissolved in water.
Moreover, the cirrhosis was defined by clinical diagnosis in
presence of liver functional insufficiency (Child Pu ¨gh = B and C)
or by liver biopsies in the case of initial chronic hepatopathy
without clear liver laboratoristic function tests of cirrhotic
evolution (Child Pu ¨gh=A). All patients with CHC, LC, CHD
and LCD had transaminase values (AST and ALT) higher than
control range, evaluated in healthy donors. Moreover, liver
cirrhosis patients presented higher birilubin values and lower
albumin and platelets count (PLT) respect to control range. Both
CHD and LCD had hyperglycemia. All patients had normal
alpha-fetoprotein (AFP) values and did not present cancer. The
patients with T2D, CHD and LCD were overweight with BMI
values in the range between 25–29 kg/m
2 whereas those with only
CHC and LC have BMI of about 25 kg/m
2. The smoking status
was known only for T2D patients.
For this study we obtained ethics approval from the ethics
committee at our institution (INT ‘‘G. Pascale’’ – CROM) and
obtained written informed consent from all involved participants.
BioPlex Assay
Blood samples were collected from a peripheral vein and kept
on ice. Serum was collected by centrifugation (3,000 rpm for
10 min at 4uC), aliquoted, and stored at 280uC until analyzed. A
multiplex biometric ELISA-based immunoassay, containing dyed
microspheres conjugated with a monoclonal antibody specific for
a target protein was used according to the manufacturer’s
instructions (Bioplex, Bio-Rad Lab., Inc., Hercules, CA, USA).
Soluble molecules were measured using three commercially
available kits: i) 21-Plex panel: IL-1a, IL-2R, IL-3, IL-12p40,
IL-16, IL-18, CCL27, CXCL1, CXCL9, CXCL12, HGF, IFN-
a2, LIF, MCP-3, M-CSF, MIF, b-NGF, SCF, SCGF-b, TNF-b,
TRAIL; ii) 10-Plex panel: C-peptide, ghrelin, GIP, glp-1,
glucagon, insulin, leptin, PAI-1, resistin, visfatin and iii) 2-Plex
panel: adiponectin and adipsin.
Each experiment was performed in duplicate using the same
procedure described in our recent papers [10,13]. Serum levels of
all proteins were determined using a Bio-Plex array reader
(Luminex, Austin, TX) that quantifies multiplex immunoassays in
a 96-well plate with very small fluid volumes. The analytes
concentration was calculated using a standard curve, with software
provided by the manufacturer (Bio-Plex Manager Software).
Data Analysis and Statistics
The nonparametric Mann-Whitney U test was used to evaluate
differences between cytokine, chemokine and growth factor ratios
in the patients and healthy controls. In particular p,0.05 is
indicated with *, p,0.01 with **, and p,0.001 with ***. T-test
was used to compare the serum levels of these proteins evaluated
in different patients groups. The correlations between the cytokine
levels and clinical/biochemical data were determined using the
Pearson correlation coefficient. Values of p,0.05 were considered
to be statistically significant. Multivariate logistic regression
analysis was performed to evaluate associations between levels of
significant cytokines/adipokines and smoking status, hypertension,
BMI, and hypercholesterolemia. Odds ratios (OR) and 95%
confidence intervals (95% CI) for association between each
cytokine and four parameters were estimated using unconditional
logistic regression models. In details, OR represent a measure of
the strength of association between variables and, when OR is
greater then 1, it indicates that the association is significant. The
statistical programs Prism 4 (GraphPad Software, San Diego, CA,
USA) and MedCalc (MedCalc software, Mariakerke, Belgium)
were employed.
Results
Comparison between Patients with Type 2 Diabetes and
Healthy Donors
In Figures 1–2 and in Table 2 we report the proteins that show
different serum levels in the type 2 diabetes (T2D) patients respect
to controls; data that were not statistically significant are not
reported. Greater amounts of IL-1a, IL-2R, IL-12, IL-18, HGF,
MIF, glucagon, insulin, leptin, PAI-1, resistin and adipsin and
lower of ghrelin were secreted by T2D patients. The significantly
increased serum levels of four pro-inflammatory interleukins (IL-
1a, IL-2R, IL-12 and IL-18) are in agreement with already
published data [15–16] that showed and confirmed how the
inflammation course is more severe in diabetic patients than in
non-diabetic subjects. Elevated HGF and MIF levels were
indicated as markers of atherosclerotic and cardiomyopathic
complications in T2D patients, respectively [17–18]. On the other
hand, the increased levels of leptin, insulin, resistin and adipsin
and the decreased levels of ghrelin are certainly correlated
between them because adipsin is activated by insulin, whereas
ghrelin and leptin exert antagonistic effects via their specific
receptors. In fact, in hepatocytes ghrelin reduces and leptin
augments insulin signal transduction [19]. Also, it has recently
shown that the levels of resistin are correlated to those of leptin
and that both these adipokines induce increased procoagulability
in diabetes mellitus [20,21]. Certainly, the elevated concentrations
of glucagon in T2D patients depend from its role in dysregulated
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[22]. Finally, since the platelet function is enhanced in T2D
patients, the increased levels of PAI-1 (plasminogen activator
inhibitor type 1) are considered to be a risk factor of cardiovascular
diseases in these patients [23]. Since smoking status was known for
T2D patients, we have subdivided them in two different
subgroups, i.e. smokers and not smokers, and compared their
cytokine levels to understand what proteins were related to
cigarette smoking. The analysis showed that there were no
statistically significant differences for the cytokines between the
two subgroups of patients.
Then, we have correlated the serum levels of all the significant
proteins in T2D patients with clinical/biochemical data by Pearson
correlationcoefficient(Table3).Inthesepatients,IL-18,resistinand
MIF showed a significant correlation with BMI and glycemia levels
(see Table 2). This result confirms these three proteins can be
considered as predictors of inflammatory activation during the
progression of T2D,as recentlyreported [21].
Comparison between Patients with Chronic CHC
Hepatitis and Healthy Donors
In CHC patients greater amounts of IL-1a, IL-2R, IL-12, IL-
18, CXCL1, CXCL9, MIF, b-NGF, C-peptide, GIP, insulin,
leptin, PAI-1, resistin, adiponectin and adipsin and lower of
ghrelin were secreted with respect to healthy controls (Figures 1–2
and Table 2).
The increased serum levels of IL-1a, IL-2R, CXCL1, CXCL9,
MIF and b-NGF agree with our recently published data [13] since
they are all pro-inflammatory cytokines involved in the immune
response to CHC and drive liver damage. Moreover, during
inflammation both IL-12 and IL-18 are produced by macro-
phages, work together in inducing cell-mediated immunity and
stimulate the production of CXCL9 [24].
Also in literature, increased levels of leptin, resistin and
adiponectin as well as of PAI-1 have been found in CHC patients
and they have been correlated to the severity of fibrosis and,
hence, indicated as marker in detecting HCC when the
carcinogenesis is affected by CHC infection [25–26].
In general, C-peptide serves as an important link between the
insulin chains and facilitates the efficient assembly, the folding and
the processing of insulin in the endoplasmic reticulum. Higher C-
peptide and insulin levels in CHC patients were already reported
supporting the hypothesis that insulin resistance may contribute to
fibrotic progression in CHC infection [5]. The secretion of adipsin,
as reported above, is activated by insulin [19] whereas GIP (called
gastrointestinal inhibitory peptide) induces insulin secretion [27].
Hence the increased levels of GIP, adipsin and insulin as well as of
leptin, that augments insulin signal transduction, are mainly
correlated not only between them but also with the decreased
levels of ghrelin that has been indicated as marker of the liver
fibrosis progression [19].
However, no data have been found in literature related to GIP
and adipsin evaluations in CHC patients and our integrated
analysis suggests, for the first time, a role for GIP and adipsin in
CHC-related chronic inflammation.
From the correlation of the serum levels of all the significant
proteins in CHC group with clinical/biochemical data, it is
resulted that IL-2R, MIF and b-NGF showed a positive correla-
tion coefficient with the transaminase values (Table 3), which were
higher in these patients than in healthy controls. This confirms the
role of these proteins as index of immune activation according to
our recently published data [13].
Table 1. Biochemical characteristics of all patients.
T2D CHC CHD LC LCD Control range
Age 61,8 62,54 65,2 70 71,8 60,92
Gender 11M/6F 10M-10F 7M-3F 8M-12F 5M-5F 9M-11F
Hypertension 17 10 3 11 3
Hypercholesterolemia 17 5 6 5 7
Cigarette smoking 12 n.d. n.d. n.d. n.d.
BMI (kg/m
2) 27,461 24,260,9 28,161,2 24,460,8 27,961,4 ,25
Total cholesterol (mg/dL) 192621 17065,8 18164,6 18267,2 20062,1 130–200
Triglycerides (mg/dL) 179621 98623 111635 105627 117636 40–165
AST (IU/L) 3164 71,4362,3 66,464,5 81,25 112,1 5–40
ALT (IU/L) 3366 121,1 104 71,96 106,7 7–56
TotBilirubin (mg/dL) 1,0160,06 0,94 1,03 1,72 1,58 0,20–1,30
Albumin (g/dL) 4,260,9 4,01 4,44 2,61 3,4 3,5–5
PLT (mL) 198464610221 187413 162000 113875 114833 150000–400000
CHC – PCR RNA negative positive positive positive positive
CHC genot negative 1:11; 2:9 1:6; 2:4 1:12; 2:8 1:7; 2:3
Glycemia (mg/dL) 145,9612,3 86 139,2 88,3 132,5 70–105
Creatinine (mg/dL) 0,960,01 0,9 0,8 1 1,1 0,6–1,36
AFP (ng/mL) ,10 ,10 ,10 ,20 ,20
Child Pu ¨gh A:8; B:7;C:5 A:3; B3;C:4
1n.d. = not detected.
We report the number of patients to which some parameters refer. For clinical data the mean value and the related control range, evaluated in healthy donors, are
shown.
doi:10.1371/journal.pone.0039486.t001
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those with Chronic CHC Hepatitis
In both T2D and CHC patients, IL-1a, IL-2R, IL-12, IL-18,
MIF, insulin, leptin, PAI-1, resistin and adipsin are increased
whereas ghrelin is decreased with respect to healthy controls
(Table 2 and Figures 1–2). We used T-test to compare the serum
levels of these proteins evaluated in different patients groups. In
particular, IL-2R, IL-12, IL-18, MIF, resistin and adipsin have
similar concentrations in both diseases. In CHC patients ghrelin
and leptin levels are lower than those with T2D (with p-value
,0.05) whereas IL-1a, insulin and PAI-1 levels are higher (with p-
value ,0.05).
Moreover, CXCL1, CXCL9, b-NGF, C-peptide, GIP and
adiponectin are higher only in CHC patients in agreement with
previous studies in which these molecules were found elevated only
in diabetic patients with complications (nephropathy, retinopathy
and atherosclerotic lesions) [28–32].
On the other hand, HGF and glucagon are higher only in T2D
patients and this confirms that glucagon and HGF play a specific
role in glucose production and homeostasis [23] and in the
progression of chronic inflammation to liver cirrhosis and cancer
[13], respectively.
Patients with Chronic CHC Hepatitis and Type 2 Diabetes
(CHD)
In CHD patients greater amounts of IL-1a, IL-2R, IL-12, IL-
18, CXCL1, CXCL9, HGF, MIF, b-NGF, C-peptide, GIP,
glucagon, insulin, leptin, PAI-1, resistin, adiponectin and adipsin
and lower of ghrelin were secreted than in healthy controls
(Figures 1–2 and Table 2). Since in CHD patients there are
increased levels of the same molecules resulted significant in type 2
diabetes and/or CHC patients, we compared by T-test the serum
concentrations in CHD patients and those evaluated in patients
having only type 2 diabetes or CHC to understand what cytokines
change or unchange in presence of both diseases.
The levels of MIF, insulin, ghrelin, leptin, glucagon, resistin and
adipsin are similar in type 2 diabetes and CHD patients whereas
IL-1a, IL-2R, IL-12, IL-18, HGF, and PAI-1 are higher in CHD
patients than in type 2 diabetes patients (with p-value ,0.01).
Figure 1. Significant cytokines in some patient groups. We report the significant molecule levels from controls and patients with type 2
diabetes (T2D), chronic hepatitis C (CHC), CHC-related cirrhosis (LC), CHC hepatitis and type 2 diabetes (CHD) and CHC-related cirrhosis and type 2
diabetes (LCD), evaluated by 21-Plex panel, are plotted with box-and-whisker graphs. The boxes extend from the 25th to the 75th percentile, and the
line in the middle is the median. The error bars extend down to the lowest value and up to the highest.
doi:10.1371/journal.pone.0039486.g001
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adiponectin, adipsin and PAI-1 are similar in CHC and CHD
patients whereas IL-1a, IL-2R, IL-12, IL-18, leptin, C-peptide,
ghrelin and CXCL9 are higher in CHD patients than in CHC
patients and GIP is lower in CHD patients than in CHC patients
(with p-value ,0.01).
Overall these data highlight that the simultaneous presence of
CHC and type 2 diabetes induces an evident increase of the
following proinflammatory cytokines: IL-1a, IL-2R, IL-12, IL-18,
CXCL9, MIF and HGF. In fact, in CHD patients their levels are
higher than in type 2 diabetes or CHC patients suggesting an
associative effect of two diseases. In particular, in comparison to C-
Figure 2. Significant cytokines in some patient groups. We report the significant molecule levels from controls and patients with type 2
diabetes (T2D), chronic hepatitis C (CHC), CHC-related cirrhosis (LC), CHC hepatitis and type 2 diabetes (CHD) and CHC-related cirrhosis and type 2
diabetes (LCD), evaluated by 10+2-Plex panel, are plotted with box-and-whisker graphs. The boxes extend from the 25th to the 75th percentile, and
the line in the middle is the median. The error bars extend down to the lowest value and up to the highest.
doi:10.1371/journal.pone.0039486.g002
Cytokinome Profile Evaluation
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39486peptide, ghrelin, GIP, insulin and adiponectin, it is worth noting
that CXCL9, HGF and glucagon levels are increased in CHD
patients even if they were resulted significant in patients affected
by one only disease.
As in the case of T2D and CHC patients, we have correlated
the serum levels of all the significant proteins in CHD group with
clinical/biochemical data. In these patients both IL-18 and C-
peptide showed a significant positive correlation with transami-
nases and BMI values (Table 3). Moreover, IL-18 correlated also
with glycemia as in type 2 diabetes patients. Certainly, these data
are interesting since IL-18 is increased in both CHC and type 2
diabetes patients whereas C-peptide is increased only in CHC
patients. Therefore, an increased concentration of C-peptide
associated with elevated serum levels of transaminases can be used
as index of viral infection in diabetic hyperglycemic patients.
Patients with CHC-related Cirrhosis (LC)
Greater amounts of IL-1a, IL-2R, IL-12, IL-18, CXCL1,
CXCL9, MIF, b-NGF, HGF, C-peptide, GIP, insulin, PAI-1,
adiponectin, leptin, resistin and adipsin and lower of ghrelin were
secreted by LC patients respect to controls (Figures 1–2). These
results have evidenced that high circulating levels of these
molecules are correlated to the presence of fasting glucose in
cirrhotic patients due to reduced liver function and altered hepatic
glucose metabolism in agreement to previous papers [33–39].
However, it is important to underline that the same molecules
increased in CHC and LC patients with the sole exception of HGF
that can be used for predicting the progression to HCC in patients
with CHC-related liver disease and low albumin.
We have used the T-test to compare the levels of all the
significant proteins in CHC as well as LC patients. Insulin, PAI-1,
adiponectin, resistin and adipsin levels are similar in both groups
whereas GIP is lower in LCs than in CHC patients (with p-value
,0.05) and C-peptide, IL-1a, IL-2R, IL-12, IL-18, CXCL9, MIF,
b-NGF, HGF and leptin are higher in LCs than in CHC patients
(with p-value ,0.05). These data suggest that these pro-
inflammatory cytokines increase during the chronic inflammation
leading to LC and, then, to cancer. Since it has been reported in
Table 2. Comparison of cytokine serum levels in all patients and healthy controls.
Cytokines Controls vs T2D Controls vs CHC Controls vs CHD Controls vs LC Controls vs LCD
21-Plex
IL-1a * ** *** *** ***
IL-2R * * ** ** ***
IL-12 * * *** *** ***
IL-18 * * *** ** ***
CXCL1 ** ** ** **
CXCL9 * *** *** ***
HGF * ** ** **
b-NGF ** ** *** ***
MIF * * *** *** ***
10-Plex
C-peptide * ** ** **
Ghrelin * ** * * *
GIP ** * * *
Glucagon * * **
Insulin * ** ** ** **
Leptin ** * ** ** **
PAI-1 * ** ** ** **
Resistin * * * * *
2-Plex
Adiponectin * * * *
Adipsin * * * * *
We report P-values (p) obtained for all significant molecules in patients with type 2 diabetes (T2D), chronic hepatitis C (CHC), CHC-related cirrhosis (LC), CHC hepatitis
and type 2 diabetes (CHD) and CHC-related cirrhosis and type 2 diabetes (LCD), with respect to healthy control subjects using the nonparametric Mann-Whitney U test.
In particular p,0.05 is indicated with *, p,0.01 with **, and p,0.001 with ***.
doi:10.1371/journal.pone.0039486.t002
Table 3. Significant correlations between cytokines and
clinical/biochemical data in all patients.
Disease Cytokines Clinical Data
T2D IL-18, resistin, MIF glycemia, BMI
CHC IL-2R, MIF, b-NGF transaminase
CHD IL-18, C-peptide glycemia, transaminasi, BMI
LC CXCL1, CXCL9, HGF albumin
LCD Glucagon, HGF glycemia, BMI, albumin
We report in patients with type 2 diabetes (T2D), chronic hepatitis C (CHC),
CHC-related cirrhosis (LC), CHC hepatitis and type 2 diabetes (CHD) and CHC-
related cirrhosis and type 2 diabetes (LCD) the cytokines and the clinical/
biochemical data that correlate between them.
doi:10.1371/journal.pone.0039486.t003
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patients without cirrhosis [1,4,9], we have also compared by T-test
the levels of significant molecules in CHD and LC patients to
separate cytokines in two groups (similar or different) in order to
use them as specific markers of the two different processes. In
particular, only three molecules behave differently in CHD and
LC patients: b-NGF is higher in LC whereas glucagon and IL-18
are higher in CHD (with p-value ,0.05) (Figure 3). This suggests
that b-NGF is a pro-inflammatory protein and index of in-
flammatory process related to chronic infection leading to cirrhosis
and then to cancer, whereas glucagon and IL-18 are mainly due to
diabetes that occurs as part of the metabolic syndrome with an
increased risk of HCC. Moreover, in agreement with our recent
results [13], the levels of CXCL1, CXCL9 and HFG in patients
with LC showed a significant positive correlation among them,
and a negative correlation with the albumin values (Table 3),
which are lower in these patients in respect to controls.
Patients with CHC-related Cirrhosis and Type 2 Diabetes
(LCD)
Greater amounts of IL-1a, IL-2R, IL-12, IL-18, CXCL1,
CXCL9, MIF, b-NGF, HGF, C-peptide, GIP, insulin, PAI-1,
adiponectin, leptin, resistin, ghrelin, and adipsin and lower
amounts of ghrelin were found in LCD patients compared with
healthy donors (Figures 1–2 and Table 2). It is also evident that the
same molecules are significant in LC and LCD patients. The only
difference is represented from glucagon (with p-value ,0.05) that
is significant in LCD patients and not in LC patients. Concerning
the levels of all the significant molecules we can underline that they
are similar in two groups with the exception of IL-2R, IL-18 and
glucagon that are higher in LCD patients. This indicates that the
levels of the three molecules are due to the presence of type 2
diabetes in LC patients. Finally, from the correlation of the serum
levels of all the significant proteins in LCD group with clinical/
biochemical data (Table 3), we observe that glucagon and HGF
show a significant positive correlation among them and with
glycemia and BMI values while correlate negatively with albumin
values, which are lower in these patients compared to controls.
Discussion
In this paper we report a simultaneous and comparative analysis
of serum levels of a large panel of cytokines, chemokines,
adipokines and growth factors in patients with type 2 diabetes,
CHC, CHC-related cirrhosis, CHC and type 2 diabetes and
CHC-related cirrhosis and type 2 diabetes by BioPlex assay. Our
interest for these diseases depends from the fact that Southern Italy
shows the highest rates of type2 diabetes/obesity [40] and, also, of
liver cancer for Europe, mainly related to infection with hepatitis
viruses (i.e. CHC) [41].
A general view of the results in Table 2, shows that b-NGF,
CXCL1, CXCL9, C-peptide, GIP and adiponectin resulted up-
expressed in all the patient groups except in those with T2D
suggesting that they can be associated to the chronic CHC
infection leading to fibrotic, cirrhotic and cancer progression, also
in presence of type 2 diabetes (CHD and LCD). In fact, b-NGF is
involved in cancer growth and metastasis and it has also been
detected in diseased liver tissues [11], CXCL1 and CXCL9 have
chemotactic activities and roles in angiogenesis, inflammation and
tumor genesis [10], adiponectin is expressed on monocytes and
macrophages that mediate the stimulation of protein kinase
activated by AMP, the oxidation of fatty acids and the uptake of
glucose [42], whereas C-peptide is implicated in insulin resistance
[5] and GIP induces insulin secretion [27].
Since type 2 diabetes has been recognized as a cofactor that can
modify the course of chronic CHC infection and can be used as an
independent predictor of HCC [8], we have compared the
significant molecules in patients with T2D and CHC. In details,
we have evidenced that: i) ghrelin and leptin levels are lower in
CHC patients than in those with T2D, ii) IL-1a, insulin and PAI-1
levels are higher in CHC patients than in those with T2D, iii)
CXCL1, CXCL9, b-NGF, C-peptide, GIP and adiponectin are
higher only in CHC patients and iv) HGF and glucagon are higher
only in T2D patients.
All these molecules were analysed by Ingenuity Pathway
Analysis 7.1 (Ingenuity Systems, Inc., Redwood City, CA, USA)
that created a network on the basis of associated functions and
data mining from experimental studies reported in literature
(Figure 4 and Table S1). This graph presents five hub genes such
as STAT3 (signal transducer and activator of transcription),
NR3C1 (nuclear receptor subfamily 3, group C, member 1), NF-
kB (called also RELA), TP53 (tumor p53) and USF1 (upstream
stimulatory factor 1). In particular, STAT3 is induced from the
leptin [43] and has a role in suppressing IFN induction of STAT1-
dependent inflammatory genes, such as CXCL9 [44]. Therefore,
we can hypothesize that in T2D patients the higher level of leptin
induces the STAT3 increased expression and the related CXCL9
suppression. On the other hand, NR3C1 is the receptor to which
cortisol and other glucocorticoids bind and interacts with STAT3
and RELA [45]. The network reported in Figure 4 shows that
RELA modulates the expression of TP53, MIF, CXCL9 and IL-
1a whereas TP53 that of CXCL1, IL2R, IL-1a, MIF, PAI-1
(called also SERPINE1) and IL18. In literature it is reported that
two RELA and TP53 genes are up-expressed in CHC and liver
fibrosis [46] and this can explain because CXCL1, IL-1a IL18 and
PAI-1 as well as CXCL9 are higher in CHC patients. As regards
USF1, it is involved in the regulation of numerous genes of glucose
and lipid metabolism as well as hepatic metabolism. USF1 resulted
down-expressed during the progression of liver fibrosis in CHC
patients [47] and this explains the lower ghrelin expression in
CHC patients in respect to those with T2D.
Moreover, it is worth of note that HGF has been found normal
only in CHC patients. This growth factor stimulates mitogenic,
motogenic (including metastogenesis) and morphogenic effects on
epithelial and endothelial cells via its receptor, proto-oncogene
Met. The activation of Met by HGF binding is linked to cell
growth and survival, through activation of both the PI3-kinase/
PDK/Akt and the Ras/Raf/MEK/ERK pathways, and to cell
mobility and cytoskeletal organization via activation of the Rho-
GTPases, Rho, Rac and CDC42. HGF and Met have been
associated with progression, invasiveness and metastasis in
a number of cancer types and for these reasons their signaling is
a major target for cancer therapeutics development [48]. Hence,
HGF increased levels in all patient groups except in CHC confirm
and suggest that this protein can be used as index for predicting, in
patients with T2D, the progression of chronic inflammation to
cancer [13].
The analysis of how molecule levels change during the
progression to more advanced stages, showed that IL-1a, IL-2R,
IL-12, IL-18, CXCL9, MIF and HGF are higher in CHD, LC and
LCD than in patients with only type 2 diabetes or CHC suggesting
that these proteins are associative markers of these two diseases
and implicated in their complicance and progression.
Furthermore, we have compared cytokinomes of LC and CHD
patients to realize what molecules were significantly different in
these two stages because in literature it has been reported that
patients with chronic CHC infection and type 2 diabetes without
liver cirrhosis can evolve into hepatocarcinogenesis [8–9]. In
Cytokinome Profile Evaluation
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39486Figure 3. Mean concentrations of significant cytokines. We report the mean levels of the molecules evaluated in patients with chronic
hepatitis C (CHC) and CHC-related cirrhosis (LC) (A), and with CHC hepatitis and type 2 diabetes (CHD) and CHC-related cirrhosis and type 2 diabetes
(LCD) (B). The legends evidence the different colors used for the analyzed groups.
doi:10.1371/journal.pone.0039486.g003
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18 are higher in CHD patients (Figure 3). Hence, data evidence
that these three molecules can be associated to two different stages
of the pathological processes (CHD and LC) that may lead to
cancer. Therefore, we suggest that b-NGF can be helpful as index
of that chronic infection stage able to evolve into cirrhosis and,
then, HCC while glucagon and IL-18 can be index of the diabetes
association that occurs as part of the metabolic syndrome leading
to HCC.
In overall the obtained results evidence that the serum levels of
some cytokines, chemokines, adipokines and growth factors can be
useful for the clinical monitoring of patients because they give
specific information in regard to the progression from CHC and
LC and to that from CHD to LCD. In fact, we have evaluated the
ratio between the mean concentrations of significant molecules in
LC versus CHC patients and in LCD vs CHD patients (see Table
S2) and in Figures 3A and B the mean concentrations of all the
significant molecules are reported in order to compare quickly the
different cytokinome profiles in the disease progression of these
patients. In details, the levels of GIP are lower in LC patients than
in CHC patients whereas those of C-peptide, IL-1a, IL-2R, IL-12,
IL-18, CXCL9, MIF, b-NGF, HGF and leptin are higher in LC
patients than in CHC patients. This suggests that these proteins
can be used to monitor and follow the CHC patients and to
understand whether they are leading to LC. Comparing CHD and
LCD patients we can observe that four proteins, i.e. b-NGF,
glucagon, IL-2R and HGF, present in LCD patients concentra-
tions significantly higher than those with CHD. Therefore we
suggest that the monitoring of these four molecules can be useful to
improve the prognosis of CHD patients.
At present our data are only indicative of HCC risk only
showing that cytokines are up-expressed in CHD, LCD and LC as
stage before cancer. However, we have already planned to collect
sera of HCC patients with or without T2D to identify the
cytokinome profile of these patients and explain what cytokines
can be marker of HCC risk.
Moreover, we have correlated the serum levels of all the
significant proteins in each group with clinical/biochemical data
Figure 4. Ingenuity Pathway Analysis (IPA) of significant molecules. The graph shows the closely associated network for significant
cytokines, reported also in Table 2, (evidenced with grey symbols) and other molecules (evidenced with white symbols) obtained by IPA software.
doi:10.1371/journal.pone.0039486.g004
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evidenced that: i) in T2D patients IL-18, resistin and MIF
correlated positively with glycemia and BMI levels, ii) in CHC
patients IL-2R, MIF and b-NGF correlated positively with
transaminase values, iii) in CHD patients IL-18 and C-peptide
correlated positively with transaminase, BMI and glycemia values,
iv) in LC patients CXCL1, CXCL9 and HFG correlated
negatively with albumin values and v) in LCD patients glucagon
and HGF correlated positively with BMI and glycemia values and
negatively with albumin values. All the results have suggested the
possibility to use mini-panels composed from cytokines and
biochemical data for discriminating the various stages of these
diseases.
To evaluate the possible association between the serum levels of
all the significant proteins in each group and smoking status,
hypertension, BMI, and hypercholesterolemia, we performed
a multivariate regression analysis using the cytokines as dependent
variables and these parameters as independent variables (Table 4).
In particular, the smoking status was known only for T2D patients.
As evidenced from odds ratios (OR) higher than 1, BMI values
resulted positively related to high levels of IL-8, resistin and MIF in
T2D patients, of IL-18 and C-peptide in CHD patients and of
glucagon and HGF in LCD patients. On the other hand, cytokine
levels were not associated with hypertension and hypercholester-
olemia in all the groups as well as with the smoking status in T2D
patients (data not shown).
In overall, our observations demonstrate that an integrated
approach (multiplex bead-based assays) is much more powerful
than isolated measurements to evaluate specific stages of these two
complex pathologies (type 2 diabetes and chronic CHC hepatitis)
alone or when they are concomitant in a patient. Reproducibility
(coefficient of variance), degree of multiplexing (plex level),
reliability (publication history) and higher sensitivity are the best
feature of this assay. The interconnected, vital extracellular
signaling networks of cytokines, are at least as complex as
intracellular signaling pathways. Cellular signals when released
into the extracellular milieu are strongly diluted and, hence, the
detection of multiple cytokines is necessary to get a more global
view of these signals. The less that is known about a particular
physiologic or pathologic mechanism directed by cytokine
signaling, the greater the need to use multiplexed cytokine
detection. However, when we are monitoring changes in levels
in certain disease conditions, what is important is to have a correct
ratio between the cytokines expressed at high concentration
compared to those expressed at very low concentrations to the
limits of detectability in experiments which follow these changes
dynamically over time. The correct ratio is much more important
than single measured quantities because it represents the balance
of population among the signaling molecules, also it makes the
results more significant because internally consistent. Therefore,
the multiplex assay has emerged as an accurate, simple, specific,
noninvasive, reproducible and less expensive method that, in
Table 4. Multivariate regression analysis using the cytokines as dependent variables and smoking status, hypertension, BMI, and
hypercholesterolemia as independent variables.
Cytokines OR (95% CI)
T2D CHC CHD LC LCD
21-Plex
IL-1a 0.66 (0.32–1.12) 0.72 (0.44–1.06) 0.69 (0.39–1.02) 0.88 (0.69–1.11) 0.79 (0.49–1.08)
IL-2R 0.65 (0.21–1.01) 0.79 (0.48–1.04) 0.72 (0.42–1.01) 0.85 (0.48–1.10) 0.81 (0.55–1.10)
IL-12 0.74 (0.50–1.05) 0.78 (0.52–1.01) 0.65 (0.49–1.11) 0.77 (0.48–1.05) 0.80 (0.58–1.09)
IL-18 5.36 (3.51–7.65) 0.81 (0.56–1.15) 4.51 (3.95–5.23) 0.79 (0.45–1.21) 1.01 (0.89–1.20)
CXCL1 0.77 (0.42–1.05) 1.01 (0.72–1.41) 0.94 (0.55–1.29) 0.95 (0.78–1.20)
CXCL9 0.81 (0.49–1.07) 0.99 (0.58–1.09) 0.95 (0.51–1.28) 0.91 (0.79–1.13)
HGF 1.06 (0.52–1.55) 1.01 (0.71–1.44) 0.88 (0.71–1.15) 3.45 (2.74–4.76)
b-NGF 0.74 (0.47–1.08) 0.79 (0.50–1.13) 0.79 (0.50–1.09) 0.89 (0.71–1.10)
MIF 2.36 (1.91–4.01) 0.80 (0.59–1.04) 0.81 (0.57–1.11) 0.90 (0.68–1.12) 0.94 (0.75–1.12)
10-Plex
C-peptide 0.69 (0.41–1.00) 1.86 (1.55–3.92) 0.87 (0.75–1.13) 1.00 (0.78–1.22)
Ghrelin 0.71 (0.44–1.10) 0.78(0.49–1.09) 0.80 (0.64–1.00) 0.93 (0.73–1.22) 0.92 (0.79–1.10)
GIP 0.75 (0.44–1.10) 0.78 (0.52–1.09) 0.76 (0.59–1.12) 0.89 (0.70–1.08)
Glucagon 0.73 (0.41–1.07) 0.99 (0.59–1.14) 2.77 (1.98–3.89)
Insulin 0.92 (0.56–1.45) 0.74 (0.45–1.05) 1.01 (0.79–1.23) 0.89 (0.66–1.11) 0.88 (0.75–1.06)
Leptin 0.65 (0.43–0.99) 0.84 (0.50–1.10) 1.00 (0.77–1.19) 0.91 (0.76–1.21) 0.89 (0.66–1.09)
PAI-1 0.44 (0.21–1.01) 0.90 (0.74–1.11) 1.03 (0.75–1.30) 0.79 (0.54–1.13) 0.95 (0.79–1.19)
Resistin 1.99 (1.52–3.21) 0.71 (0.52–1.02) 1.05 (0.75–1.28) 0.85 (0.57–1.09) 0.99 (0.78–1.21)
2-Plex
Adiponectin 0.69 (0.40–0.99) 0.98 (0.79–1.19) 0.79 (0.60–1.07) 0.70 (0.51–1.00)
Adipsin 0.55 (0.38–1.04) 0.73 (0.50–1.03) 1.01 (0.68–1.19) 0.84 (0.51–1.05) 0.72 (0.49–1.08)
We report odds ratios (OR) and 95% confidence intervals (95% CI) evaluated for association between each significant cytokine (shown in Table 2) and BMI in patients
with type 2 diabetes (T2D), chronic hepatitis C (CHC), CHC hepatitis and type 2 diabetes (CHD), CHC-related cirrhosis (LC), and CHC-related cirrhosis and type 2 diabetes
(LCD). OR being positively associated (higher than 1) to cytokines are evidenced in bold.
doi:10.1371/journal.pone.0039486.t004
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association of type 2 diabetes and/or CHC to liver cirrhosis, and
to improve the prognosis of these diseases. Work is already in
progress to collect in specialized databanks as much data is
possible on cytokinomes determined by multiplexing as well as
clinical/biochemical data to distinguish and evaluate quantitative-
ly the pathological patterns of these patients by a neural network
approach [49]. Of course the presence of protein chips able to
evaluate comparatively the amounts of a high number of cytokines
is an important prerequisite to improve the discriminating ability
of this approach as well as the decision-making ability of the neural
networks.
In conclusion our working hypothesis was i) to understand if the
cytokinome profiles can be used to distinguish the patients with
only CHC or T2D or with both diseases, ii) to identify what
cytokines present concentrations similar or different in CHD and
LC patients because in the literature it has reported that T2D can
be associated with HCC in HCV patients without cirrhosis iii) to
identify what cytokines can be useful for the clinical monitoring of
patients in the progression from CHC and LC and to that from
CHD to LCD and iv) to define the prognostic mini-panels for
these diseases based on biochemical data and cytokines. The
results obtained in our paper have evidenced that some cytokines
are significantly up-regulated in patients with only CHC or T2D
whereas other cytokines increase when both the diseases are
present. Moreover, from the comparison between the levels of
significant molecules in CHD and LC patients, it is resulted that
three molecules present different behavior in these patients: b-
NGF is higher in LC whereas glucagon and IL-18 are higher in
CHD. Therefore we suggest that b-NGF is a pro-inflammatory
protein and index of inflammatory process related to chronic
infection leading to cirrhosis and, then, to cancer whereas
glucagon and IL-18 are due mainly to the diabetes and occurs
as part of the metabolic syndrome that can increase the risk of
HCC. Also our results have evidenced what cytokines change in
the progression from CHC and LC and to that from CHD to
LCD. Finally our studies have demonstrated that some molecules
have significant correlations and associations with clinical/bio-
chemical data (see Tables 3 and 4), and defined mini-panels that
can be used as specific markers for the different disease staging.
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